Clinical Trials

Phase 1 Active not recruiting

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT04891757 2025-07-10

FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies

144 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT03066648 2025-05-18

Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS

241 enrolled

Phase 1 Active not recruiting

Bone Marrow Diseases, Hematologic Diseases, Leukemia, Leukemia, Myeloid, Myelodysplastic Syndromes, Preleukemia, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT04623944 2024-12-27

NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS

61 enrolled

130 enrolled 34 charts 2 FDA

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT02103478 2024-08-27

Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS)

Phase 1/2 Completed

Myeloid

Myelodysplastic Syndromes

NCT03306264 2024-08-27

Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML

Phase 3 Completed

227 enrolled 37 charts 2 FDA

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT00042003 2024-08-02

Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Blast Phase Who Are Refractory to Imatinib Mesylate (Gleevec)

40 enrolled

Blast Crisis, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00043381 2024-08-02

Decitabine Versus Supportive Care in Adults With Advanced-stage MDS

Phase 3 Completed

160 enrolled

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT03813186 2024-08-02

Effect of Food on Blood Levels of ASTX727

18 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT03593915 2023-11-09

A Phase 1b/2 Study of Alvocidib Plus Decitabine or Azacitidine in Patients With MDS

Phase 1/2 Terminated

20 enrolled 13 charts

Myelodysplastic Syndromes, Neoplasms, Leukemia, Myelomonocytic, Chronic

NCT05426798 2022-06-22

Clinical Study of TQB2618 Injection in Combination With Demethylation Drugs in Patients With Recurrent/Refractory Acute Myeloid Leukemia, Myelodysplastic Syndromes

Phase 1 Unknown

73 enrolled

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute

NCT04283526 2021-03-04

Study of Select Combinations in Adults With Myelofibrosis

Phase 1 Withdrawn

Myeloid

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

NCT01546038 2020-03-03

A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

255 enrolled 82 charts 1 FDA

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT01211457 2019-07-16

Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)

Phase 1/2 Unknown

65 enrolled

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute

NCT00479232 2015-09-21

Phase I Trial of Vorinostat (MK-0683, SAHA) in Combination With Decitabine in Patients With AML or MDS (MK-0683-055 EXT1)

71 enrolled 9 charts

Leukemia, Myelodysplastic Syndromes

NCT00760084 2011-08-08

Trial of Decitabine in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome

10 enrolled 7 charts

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT01378416 2011-07-12

Pharmacokinetic Trial of Decitabine (Dacogen) Administered as a 3-hour Infusion to Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome

16 enrolled 10 charts

Leukemia, Myelodysplastic Syndromes, Neoplasms, Leukemia, Myeloid, Acute

NCT00042016 2009-10-14

Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Chronic Phase Who Are Refractory to Imatinib Mesylate (Gleevec)

40 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00041990 2007-12-17

Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Accelerated Phase Who Are Refractory to Imatinib Mesylate (Gleevec)

40 enrolled